A phase I study of prolonged ambulatory infusion of ifosfamide with oral mesna

Chemotherapy

Volumn 51, Issue 2-3, 2005, Pages 142-146

  Olver, Ian ^a   Keefe, Dorothy ^a   Myers, Melinda ^a   Caruso, Diana ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Ambulatory infusion; Ifosfamide; Mesna; Phase I

Indexed keywords

IFOSFAMIDE; MESNA;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HEMATURIA; HUMAN; HYPOTENSION; INDUCED HYPOTENSION; LETHARGY; LIVER TOXICITY; MALE; NAUSEA; PRIORITY JOURNAL; THYROID CANCER; URINARY TRACT DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS, ALKYLATING; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MESNA; MIDDLE AGED; NEOPLASMS; PROTECTIVE AGENTS;

EID: 22144491574     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085622     Document Type: Article

References (27)

1. Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumors. J Clin Oncol 1998;16:2500-2504.
2. Ichiki M, Gohara R, Rikimaru T, Kitajima T, Fujiki R, Shimada A, Aizawa H: Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study. Chemotherapy 2003;49:200-205.
3. Antman KH, Ryan L, Elias A, Sherman D, Grier HE: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcomas. J Clin Oncol 1989;7:126-131.
4. Allen IM, Creaven PJ, Nelson RI: Studies on the human pharmacokinetics of ifosfamide (NSC 109724). Cancer Treat Rep 1976;60:451-458.
5. Skinner R, Pearson ADJ, Price I, Coulthard MG, Craft AW: Nephrotoxicity after ifosfamide. Arch Dis Child 1990;65:732-738.
6. Sakurai M, Saijo N, Shinkai T, Eguchi K, Asaki Y, Tamura T, Sano T, Suemasu K, Jett JR: The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 1986;16:153-156.
7. Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH: Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 2001;29:967-975.
8. Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV: Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999;10:1087-1094.
9. Moehler M, Gutzler F, Steinmann S, Boehme M, Raeth U, Stremmel W, Galle PR, Rudi J: Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. Chemotherapy 2003;49:438-443.
10. Lind MJ, Roberts HI, Thatcher N, Idle JR: The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 1990;26:105-111.
11. Sladek N: Metabolism of oxaphosphorine. Pharmacol Ther 1998;37:301-355.
12. Lokich J, Anderson N, Bern M, Moore C: Ifosfamide continuous infusion without mesna. A phase I trial of a 14 day cycle. Cancer 1991;67:883-885.
13. Elias AD, Eder JP, Shea T, Begg CB, Frei E 3rd, Antman KH: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990;8:170-178.
14. Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT: Pharmacokinetics of an intravenous-oral versus intravenous mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 1998;16:616-621.
15. Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP: Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res 1998;4:2313-2320.
16. Siu LL, Moore MJ: Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998;6:144-154.
17. Klein HO, Wickramanayake PD, Christian E, Coerper C: Therapeutic effects of single-push or fractionated injections or continuous infusions of oxazaphosphorines (cyclophosphamide, ifosfamide, Asia Z7557). Cancer 1984;54:1193-1203.
18. Bellmunt J, Erses N, Ribas A, Casado S, Albanell J, Baselga J: Feasibility trial of high-dose seven-day continuous ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol 1997;40:273-276.
19. Patel S, Vadhan-Raj S, Papadopoulos N, Plager C, Burgess MA, Hays C, Benjamin RS: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - Dose-response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
20. Le Cesne A, Antonie E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T: High dose ifosfamide: Circumvention of resistance to standard dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
21. Talbot SM, Rankin C, Taub RN, Balcerzak SP Jr, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH: High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Cancer 2003;98:331-336.
22. De Pas T, Curigliano G, Masci G, Catania C, Conandone A, Boni C, Tucci A, Pagani O, Marrocco E, de Braud F: Italian Sarcoma Group Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. Ann Oncol 2002;13:161-166.
23. Lauro VD, Spazzapan S, Lombardi D, Paolello C, Scuderi C, Crivellari D, Magri MD, Veronesi A: Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil. Tumori 2001;87:27-29.
24. Manegold C, Drings P, Pawinski A, Lentz MA, van Glabbeke M, van Zandwijk N, Bachmann P, Schnaars Y, Skacel Z, Zatloukal P, Dolensky J, Jackevicius A, Petruzelka L, Giaccone G: Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: A randomized phase II trial of the EORTC lung cancer cooperative group. Ann Oncol 1996;7:637-639.
25. Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R: Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res 2000;6:1314-1321.
26. Frustaci S, Buonadonna A, Romanini A, Comandone A, Dalla Palma M, Gamucci T, Verusio C, Lionetto R, Dani C, Casali P, Santoro A: Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. Tumori 1999;85:229-233.
27. Campisi C, Fabi A, Papaldo P, Tomao S, Massidda B, Zappala A, Corrao G, Rea S: Ifosfamide given by continuous intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer. A phase I-II clinical trial. Cancer Chemother Pharmacol 1999;4(suppl):S1-S4.